United States · Markets & Finance · Quartz

Viatris is buying Pacira BioSciences for $1.65 billion in non-opioid pain push

Published by Quartz · United States 40 min ago

The deal, at $36.50 per share, represents a roughly 45% premium and is expected to close by the end of 2026

Read the full article on Quartz Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (qz.com)

Also worth reading

Judge Extends Pause on Trump’s Ban Against CNN, MS NOW and Politico

Business Insider

I always thought I'd settle down in Canada. Living in Japan for a year changed my mind.

Apple appoints new M&A chief under CEO Ternus: report

Watch the trailer for ‘The Altruists,’ Netflix’s show about the FTX scandal

Here’s what happened in crypto today

Solana DeFi Firms Orca and Loopscale Merge Under New Formation Brand